Monday, October 26, 2026

10-Year Treasury Yields Jump to 4.42% as High-Valuation AI Stocks Face Compression

The 10-year Treasury yield climbed from 3.96% to 4.42%, creating valuation pressure across equity markets. Unprofitable AI companies face steeper declines than profitable peers as the higher discount rate environment reshapes investment strategies. The S&P 500 approached correction territory by March 29, 2026.

LM Salvado
LM Salvado

March 31, 2026

10-Year Treasury Yields Jump to 4.42% as High-Valuation AI Stocks Face Compression
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

The 10-year Treasury yield surged from 3.96% to 4.42%, tightening financial conditions for growth stocks and amplifying valuation concerns across technology sectors.1 The move represents a structural shift in discount rates that disproportionately impacts companies without near-term earnings.

"The cost of capital is the governing constraint in current financial markets," according to market analysis.1 Investors face adjustments to higher discount rates that weigh directly on equity valuations, particularly for growth-oriented positions.

AI stocks split along profitability lines during the yield surge. Companies with established revenue streams show resilience while unprofitable firms experience accelerated compression. The pattern suggests a 2x performance gap between profitable and unprofitable AI names when yields rise more than 25 basis points.1

Palantir declined from November highs despite launching new AI integration products, illustrating how rate sensitivity overrides product momentum for high-multiple stocks.1 The S&P 500 neared correction levels by March 29, reflecting broad market repricing under elevated yield conditions.1

Trading strategies now prioritize cash flow generation over growth narratives. Portfolio managers rotate toward profitable technology companies while reducing exposure to speculative AI plays. The yield environment forces fundamental reassessment of valuations built during the low-rate period.

Options markets price increased volatility for unprofitable tech names. Implied volatility spreads widened between profitable and unprofitable AI sectors, creating opportunities for dispersion trades. Market makers adjust delta hedging as correlation patterns shift under rate pressure.

The Treasury curve steepening suggests sustained pressure on long-duration assets. Fixed income alternatives compete more effectively with equity risk premiums, particularly for growth stocks trading above 10x sales. Investors recalibrate position sizing as the opportunity cost of equity exposure rises with bond yields.

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com